Compare Enveric Biosciences Inc (ENVB) vs NIO Inc. (NIO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs NIO Inc. — how do they compare? Enveric Biosciences Inc trades at $1.48 (market cap $6.80M), while NIO Inc. trades at $3.6 (market cap $8.62B). The key difference: NIO Inc. is far larger — about 1267.6× Enveric Biosciences Inc's market cap, and Enveric Biosciences Inc is more actively traded (64,867 versus 39,648,517). Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and NIO Inc. for 81 Days on average.
| ENVB | NIO | |
|---|---|---|
Market Cap | $6.80M | $8.62B |
Volume | 64,867 | 39,648,517 |
Sector | Health | Consumer Cyclical |
52-Week High | $10.80 | $7.46 |
52-Week Low | $1.27 | $3.37 |
Typical Hold Time | 14 Days | 81 Days |
Enterprise Value | -$1.49M | $6.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.45, down 3.01% on the day, with a bearish technical signal driven by moving averages. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten quarterly EPS expectations. Recent positive developments include a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in investor conferences.
The outlook is mixed; analyst consensus is 75% buy with strong earnings beats, but high negative ROE/ROA and operational cash burn pose significant risks. Investment opportunity hinges on successful drug development, while key risks include funding needs and clinical trial outcomes.
NIO trades at $3.60, up 1.69% today but near 52-week lows, with technical indicators showing bearish momentum. The company reported Q3 2026 deliveries up 25.4% and recently completed a strategic battery-swapping partnership with Geely. Despite revenue growth to $87.49B in 2025, NIO continues to post significant losses with a -17.8% net margin. Analyst consensus remains positive with a $6.23 price target, though technical signals and cash flow challenges present headwinds.
NIO's growth trajectory and strategic partnerships offer long-term potential, but investors face substantial execution risks amid persistent losses and competitive pressures. The stock's current discount to analyst targets presents opportunity, but requires careful monitoring of profitability improvements and market share sustainability in the crowded EV sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About NIO Inc.
NIO Inc. manufactures and sells automobiles. The Company offers electric vehicles and parts, as well as provides battery charging services. NIO serves customers worldwide.
Read more on NIO →
